Mechanisms of hyponatremia in patients with decompensated liver cirrhosis treated with terlipressin and related treatment principles
10.3969/j.issn.1001-5256.2016.11.043
- VernacularTitle:特利加压素治疗失代偿期肝硬化并发低钠血症的机制和处理原则
- Author:
Jia YOU
1
;
Jiaji JIANG
Author Information
1. Liver Diseases Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
- Publication Type:Research Article
- Keywords:
liver cirrhosis;
hyponatremia;
lysine vasopressin;
review
- From:
Journal of Clinical Hepatology
2016;32(11):2191-2194
- CountryChina
- Language:Chinese
-
Abstract:
Esophagogastric variceal bleeding and hepatorenal syndrome are common complications in patients with decompensated liver cirrhosis and portal hypertension. Terlipressin can lead to the constriction of visceral vessels, reduce portal venous pressure, and increase renal perfusion and is the first-line drug. In recent years, it has been reported that some patients experienced hyponatremia during the treatment with terlipressin. Since patients with liver cirrhosis tend to develop hyponatremia, the application of terlipressin may have an adverse effect on the management of serum sodium level in such patients. This article summarizes the incidence rate of hyponatremia during terlipressin treatment and related risk factors and introduces the pathogenesis of hyponatremia during terlipressin treatment in patients with decompensated liver cirrhosis and the treatment principles for hyponatremia. If the occurrence of hyponatremia can be controlled, terlipressin may be an effective drug for the treatment of portal hypertension.
